

# Nobuharu Tamaki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9400119/publications.pdf>

Version: 2024-02-01

109  
papers

3,055  
citations

147566

31  
h-index

205818

48  
g-index

115  
all docs

115  
docs citations

115  
times ranked

3069  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. <i>Hepatology</i> , 2010, 52, 518-527.	3.6	265
2	Î±-fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. <i>Hepatology</i> , 2013, 58, 1253-1262.	3.6	227
3	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Journal of Gastroenterology</i> , 2021, 56, 951-963.	2.3	114
4	Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor Î± modulator (SPPARMÎ±), versus placebo in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 54, 1263-1277.	1.9	90
5	Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. <i>Nature Reviews Endocrinology</i> , 2022, 18, 55-66.	4.3	82
6	Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. <i>Hepatology Research</i> , 2018, 48, 821-828.	1.8	74
7	Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation. <i>Oncology</i> , 2011, 80, 278-288.	0.9	67
8	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. <i>Hepatology Research</i> , 2010, 40, 870-877.	1.8	65
9	A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. <i>Hepatology Research</i> , 2010, 40, 251-260.	1.8	58
10	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Hepatology Research</i> , 2021, 51, 1013-1025.	1.8	58
11	Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. <i>Cancer</i> , 2014, 120, 229-237.	2.0	57
12	<i>Wisteria floribunda</i> agglutinin positive human Mac-2 binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. <i>Hepatology Research</i> , 2015, 45, E82-8.	1.8	55
13	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. <i>Hepatology</i> , 2012, 55, 20-29.	3.6	54
14	L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015, 13, 1540-1543.	2.4	53
15	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2022, 162, 680-688.	0.6	53
16	Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. <i>PLoS ONE</i> , 2018, 13, e0198812.	1.1	51
17	Up to seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. <i>Hepatology Research</i> , 2018, 48, 442-450.	1.8	49
18	Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 2004-2010.	1.4	48

#	ARTICLE	IF	CITATIONS
19	Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. <i>Gut</i> , 2022, 71, 983-990.	6.1	45
20	Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. <i>Journal of Gastroenterology</i> , 2014, 49, 1495-1503.	2.3	44
21	Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. <i>World Journal of Gastroenterology</i> , 2013, 19, 249.	1.4	44
22	Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013, 20, 72-76.	1.0	42
23	Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0231828.	1.1	42
24	<i>Wisteria floribunda</i> agglutinin- $\alpha$ 2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. <i>Hepatology Research</i> , 2018, 48, 1131-1139.	1.8	40
25	Placebo effect on progression and regression in NASH: Evidence from a meta-analysis. <i>Hepatology</i> , 2022, 75, 1647-1661.	3.6	39
26	Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 292-301.	1.9	38
27	Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. <i>Hepatology Research</i> , 2015, 45, E115-21.	1.8	37
28	Urinary excretion of the water channel aquaporin-2 correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. <i>Journal of Gastroenterology</i> , 2016, 51, 620-627.	2.3	36
29	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2960-2966.	1.4	36
30	Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. <i>Investigational New Drugs</i> , 2022, 40, 392-402.	1.2	36
31	Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , 2011, 16, 685-694.	0.6	35
32	Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016, 11, e0154558.	1.1	34
33	Metabolic Associated Fatty Liver Disease Increases the Risk of Systemic Complications and Mortality. A Meta-Analysis and Systematic Review of 12,620,736 Individuals. <i>Endocrine Practice</i> , 2022, 28, 667-672.	1.1	34
34	Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. <i>Liver Transplantation</i> , 2014, 20, 291-297.	1.3	33
35	Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma—Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. <i>Cancers</i> , 2019, 11, 1517.	1.7	30
36	New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode. <i>PLoS ONE</i> , 2019, 14, e0221548.	1.1	29

#	ARTICLE	IF	CITATIONS
37	Magnetic resonance elastography plus Fibrosis <sup>4</sup> versus FibroScan <sup>4</sup> aspartate aminotransferase in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , 2022, 75, 661-672.	3.6	29
38	Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2014, 49, 1152-1162.	2.3	28
39	Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. <i>Annals of Laboratory Medicine</i> , 2021, 41, 16-24.	1.2	27
40	Non-alcoholic fatty liver disease fibrosis score and FIB <sup>4</sup> scoring system could identify patients at risk of systemic complications. <i>Hepatology Research</i> , 2015, 45, 667-675.	1.8	26
41	Noninvasive assessment of liver fibrosis and its clinical significance in nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2022, 52, 497-507.	1.8	26
42	Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2019, 26, 893-899.	1.0	25
43	<i>Wisteria floribunda</i> agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2019, 9, 10109.	1.6	24
44	Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. <i>PLoS ONE</i> , 2017, 12, e0174649.	1.1	24
45	Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 2533-2541.e7.	2.4	24
46	Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. <i>PLoS ONE</i> , 2019, 14, e0211122.	1.1	23
47	Changes in the components and content of biological water in the brain of experimental hydrocephalic rabbits. <i>Journal of Neurosurgery</i> , 1990, 73, 274-278.	0.9	22
48	Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. <i>Hepatology Research</i> , 2014, 44, 720-727.	1.8	22
49	Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. <i>PLoS ONE</i> , 2015, 10, e0137351.	1.1	22
50	Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. <i>Hepatology Research</i> , 2019, 49, 33-41.	1.8	22
51	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. <i>Hepatology Research</i> , 2020, 50, 1375-1385.	1.8	22
52	Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1171-1173.e2.	2.4	22
53	Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon. <i>Journal of Viral Hepatitis</i> , 2017, 24, 672-678.	1.0	21
54	Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e3349-e3354.	2.9	21

#	ARTICLE	IF	CITATIONS
55	Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. <i>Hepatology Research</i> , 2020, 50, 137-143.	1.8	19
56	Reduced Organic Anion Transporter Expression Is a Risk Factor for Hepatocellular Carcinoma in Chronic Hepatitis C Patients: A Propensity Score Matching Study. <i>Oncology</i> , 2014, 86, 53-62.	0.9	18
57	Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. <i>PLoS ONE</i> , 2015, 10, e0138060.	1.1	18
58	Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1595-1601.	1.4	18
59	Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2022, 15, 175628482210938.	1.4	18
60	Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. <i>Cancer Medicine</i> , 2016, 5, 3111-3120.	1.3	17
61	Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2019, 11, 1256.	1.7	17
62	Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2616-2618.	2.4	17
63	Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. <i>Liver Cancer</i> , 2016, 5, 257-268.	4.2	16
64	Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020, 92, 1355-1358.	2.5	16
65	Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110504.	1.4	15
66	Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2017, 7, 244.	1.6	14
67	Prediction of reversible ischemia after coronary artery bypass grafting by positron emission tomography. <i>Journal of Cardiology</i> , 1991, 21, 193-201.	0.8	14
68	Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy. <i>Hepatology Research</i> , 2014, 44, 319-326.	1.8	12
69	Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir. <i>JGH Open</i> , 2020, 4, 429-432.	0.7	11
70	Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2943-2951.	1.4	11
71	Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade. <i>Hepatology Research</i> , 2021, 51, 902-908.	1.8	11
72	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2021, 48, 481-487.	0.6	11

#	ARTICLE	IF	CITATIONS
73	Hepatocellular Carcinoma Risk Assessment for Patients With Advanced Fibrosis After Eradication of Hepatitis C Virus. <i>Hepatology Communications</i> , 2022, 6, 461-472.	2.0	10
74	Two-Step Strategy, FIB-4 Followed by Magnetic Resonance Elastography, for Detecting Advanced Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2023, 21, 380-387.e3.	2.4	10
75	Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 2673-2674.e3.	2.4	9
76	Living in the non-alcoholic fatty liver disease silent epidemic: a qualitative systematic review of patients' perspectives. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 570-579.	1.9	9
77	Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. <i>Scientific Reports</i> , 2020, 10, 13021.	1.6	8
78	Use of the Serum Wisteria floribunda Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients. <i>Diagnostics</i> , 2020, 10, 173.	1.3	8
79	Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2021, 93, 3744-3751.	2.5	8
80	Diagnostic Accuracy of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, e1478-e1482.	2.4	8
81	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. <i>International Journal of Molecular Sciences</i> , 2021, 22, 40.	1.8	8
82	Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. <i>Journal of Viral Hepatitis</i> , 2021, 28, 787-794.	1.0	7
83	Conversion surgery for hepatocellular carcinoma after tyrosine kinase inhibitor treatment. <i>JGH Open</i> , 2022, 6, 301-308.	0.7	7
84	Angled rigid neuroendoscope for continuous intraoperative visual monitoring: technical note. <i>Journal of Clinical Neuroscience</i> , 2001, 8, 148-150.	0.8	6
85	Impaired brain function improved by l-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy. <i>Scientific Reports</i> , 2020, 10, 13566.	1.6	6
86	Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. <i>JGH Open</i> , 2020, 4, 1183-1190.	0.7	6
87	Pretreatment Gastric Lavage Reduces Postoperative Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms. <i>PLoS ONE</i> , 2016, 11, e0149235.	1.1	5
88	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not Î±-fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. <i>International Journal of Molecular Sciences</i> , 2020, 21, 3640.	1.8	5
89	Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. <i>Hepatology Research</i> , 2020, 50, 996-999.	1.8	5
90	Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. <i>JGH Open</i> , 2021, 5, 1085-1091.	0.7	5

#	ARTICLE	IF	CITATIONS
91	Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy. <i>Hepatology Research</i> , 2011, 41, 217-224.	1.8	4
92	Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2021, 51, 1172-1173.	1.8	4
93	Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma. <i>PLoS ONE</i> , 2022, 17, e0265235.	1.1	4
94	A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response. <i>JGH Open</i> , 2022, 6, 20-28.	0.7	4
95	A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia. <i>Journal of Clinical and Translational Hepatology</i> , 2022, 000, 000-000.	0.7	3
96	Viable myocardium identified by reinjection thallium-201 imaging: comparison with regional wall motion and metabolic activity on FDG-PET. <i>Journal of Cardiology</i> , 1992, 22, 283-93.	0.8	2
97	Four cases with advanced hepatocellular carcinoma who achieved long survival, after surgical resection following to down-staging therapies. <i>Acta Hepatologica Japonica</i> , 2016, 57, 649-655.	0.0	1
98	Plasma Renin Activity Predicts Prognosis and Liver Disease-Related Events in Liver Cirrhosis Patients with Ascites Treated by Tolvaptan. <i>Digestive Diseases</i> , 2022, 40, 479-488.	0.8	1
99	A case of unresectable hepatocellular carcinoma maintaining stable disease by using anti-vascular endothelial growth factor receptor antibody after the exacerbation of psoriasis due to small-molecule kinase inhibition. <i>Acta Hepatologica Japonica</i> , 2020, 61, 513-519.	0.0	1
100	Letter: predictive role of magnetic resonance elastography in chronic liver disease—still a long way to go. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 622-623.	1.9	1
101	Validation of magnetic resonance elastography plus FIB-4 for significant fibrosis in nonalcoholic fatty liver disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2022, , .	1.4	1
102	Two cases of acute liver failure caused by hepatitis A which were negative for serum IgM-HA antibody at the early stage of the onset. <i>Acta Hepatologica Japonica</i> , 2013, 54, 553-558.	0.0	0
103	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 1419-1420.	2.4	0
104	Imaging Findings of Hepatocellular Carcinoma that Developed after HCV Eradication with Direct-Acting Antivirals. <i>Acta Hepatologica Japonica</i> , 2019, 60, 46-48.	0.0	0
105	Reply to Wang et al. <i>Journal of Viral Hepatitis</i> , 2021, 28, 1335-1336.	1.0	0
106	Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients. <i>Hepatology Research</i> , 2021, 51, 1170-1171.	1.8	0
107	IV. Evaluation of Liver Fibrosis and Steatosis in Non-alcoholic Fatty Liver Disease. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020, 109, 34-41.	0.0	0
108	Letter: association of laboratory indexes and magnetic resonance elastography-associated liver stiffness with complications and mortality—authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 626-627.	1.9	0

#	ARTICLE	IF	CITATIONS
109	<scp>General evaluation score</scp> for predicting the development of <scp>hepatocellular carcinoma</scp> in patients with advanced liver fibrosis associated with <scp>hepatitis C virus</scp> genotype 1 or 2 after <scp>direct-acting antiviral</scp> therapy. JGH Open, 2022, 6, 487-495.	0.7	0